Premium
Salicylic acid (SA)‐eluting bone regeneration scaffolds with interconnected porosity and local and sustained SA release
Author(s) -
Yu Weiling,
Bajorek Jennifer,
Jayade Sayeli,
Miele Alyssa,
Mirza Javad,
Rogado Sarah,
Sundararajan Aravind,
Faig Jonathan,
Ferrage Loïc,
Uhrich Kathryn E.
Publication year - 2017
Publication title -
journal of biomedical materials research part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 150
eISSN - 1552-4965
pISSN - 1549-3296
DOI - 10.1002/jbm.a.35904
Subject(s) - materials science , regeneration (biology) , scaffold , biomedical engineering , drug delivery , salicylic acid , porosity , composite material , nanotechnology , chemistry , medicine , microbiology and biotechnology , biochemistry , biology
In previous work, we observed that localized and sustained delivery of an anti‐inflammatory drug, salicylic acid (SA), via a SA‐based polymer (SAP) powder significantly enhanced diabetic bone regeneration through long‐term mitigation of local inflammation. In this study, SAP was formulated into uniform microspheres and then sintered into a scaffold with an interconnected porous structure and modulus suitable for bone regeneration. The SAP scaffolds have ∼45% SA loading, which is the highest among drug‐eluting bone regeneration scaffolds to‐date. In addition, the scaffold provides localized, controlled and sustained SA release that has been proven to enhance diabetic bone regeneration. With the combination of physical (interconnected porosity) and chemical therapeutic features (high drug loading and sustained release), the novel SAP scaffolds offer unique therapeutic advantages and are promising diabetic bone regeneration candidates. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 105A: 311–318, 2017.